Inventor · disambiguated record
Francesca D'Addio
Also filed as: D'ADDIO FRANCESCA
4 granted patents·8 pending applications·8 citations·filing 2016–2025
67Inventor score
Top patents by PatentIndex Score
12 records- 0189US11020453B2Inhibitor of IGFBP3/TMEM219 axis and diabetesOSPEDALE SAN RAFFAELE SRL·Filed 2018·Granted Jun 1, 2021·4 cites·22 claims
- 0286US10682391B2Inhibitors of IGFBP3 binding to TMEM219 for treatment of intestinal diseasesOSPEDALE SAN RAFFAELE SRL·Filed 2016·Granted Jun 16, 2020·4 cites·10 claims
- 0369US12221485B2TMEM219 antibodies and therapeutic uses thereofENTHERA S R L·Filed 2024·Granted Feb 11, 2025·0 cites·22 claims
- 0468US2025346656A1Methods for treating diabetic kidney disease and glomerular diseaseNEPHRIS SRL·Filed 2025·Application pending·0 cites
- 0567US2021169973A1Inhibitor of IGFBP3/TMEM219 Axis and DiabetesOSPEDALE SAN RAFFAELE SRL·Filed 2021·Application pending·0 cites
- 0663US2025346652A1Methods for treating diabetic kidney disease and glomerular diseaseNEPHRIS SRL·Filed 2022·Application pending·0 cites
- 0759US12221476B2Antibodies and uses thereofOSPEDALE SAN RAFFAELE SRL·Filed 2019·Granted Feb 11, 2025·0 cites·22 claims
- 0856US2018169184A1Inhibitor of IGFBP3/TMEM219 Axis and DiabetesOSPEDALE SAN RAFFAELE SRL·Filed 2016·Application pending·0 cites
- 0955US2020316168A1Inhibitors of igfbp3 binding to tmem219 for treatment of intestinal diseasesOSPEDALE SAN RAFFAELE SRL·Filed 2020·Application pending·0 cites
- 1050US2025270306A1Antibodies and uses thereofOSPEDALE SAN RAFFAELE SRL·Filed 2025·Application pending·0 cites
- 1146US2023242649A1Tmem219 antibodies and therapeutic uses thereofENTHERA S R L·Filed 2020·Application pending·0 cites
- 1239US2023039165A1Igfbp3 antibodies and therapeutic uses thereofENTHERA S R L·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Francesca D'Addio files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →